|
See related Puregon inj[保妊康 注射劑] information |
|
|
|
製造商 |
Schering-Plough |
|
代理/經銷商 |
Zuellig |
|
成份 |
Follitropin β |
|
適應症 |
Treatment of female infertility due to anovulation (including polycystic ovarian disease, PCOD), in women who have been unresponsive to treatment with clomiphene citrate. Controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs. Men: Deficient spermatogenesis due to hypogonadotrophic hypogonadism. |
|
用量 |
SC inj only. Women Individualized dosage according to ovarian response. Anovulation Initially 50 iu daily for 7-14 days. Controlled ovarian hyperstimulation in medically assisted reproduction programs Initially at least 100-225 iu for 1st 4 days. Thereafter, the dose may be adjusted individually. Maintenance: 75-375 iu for 6-12 days. Men 450 iu/week, preferably divided in 3 dosages of 150 iu each, concomitantly with hCG, for at least 3-4 months. If patient is unresponsive, may continue for up to 18 months or longer. |
|
過量 |
View Puregon[保妊康] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. |
|
禁忌 |
Ovarian, breast, uterine, pituitary or hypothalamic tumours. Pregnancy, lactation. Undiagnosed vag bleeding. Primary ovarian failure. Ovarian cysts or enlarged ovaries, not related to PCOD. Sexual organ malformations incompatible with pregnancy. Uterine fibroid tumours incompatible with pregnancy. Primary testicular failure. |
|
注意事項 |
Exclude presence of uncontrolled non-gonadal endocrinopathies (eg thyroid, adrenal or pituitary disorders). Predisposition to thrombosis. Women: Perform baseline & periodic ultrasonographic assessment of follicular development & determination of oestradiol levels. Men: Conduct semen analysis 4-6 months after start of therapy. Hypersensitivity to streptomycin or neomycin. |
|
不良反應 |
Local inj site reactions. In women: Ovarian hyperstimulation, ectopic pregnancy, multiple gestations, thromboembolisms. In men: Gynecomastia, acne.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Concomitant use with clomiphene citrate may enhance the follicular response. A higher dose may be needed after pituitary desensitisation induced by a GnRH agonist.
View more drug interactions with Puregon[保妊康] |
|
使用上注意 |
For caution against possible variation of physical aspect of medicine... click to view Puregon[保妊康] detailed prescribing infomation |
|
儲存 |
View Puregon[保妊康] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Puregon[保妊康] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Puregon[保妊康] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Puregon 注射劑 |
|
Puregon (Vial) 50 IU x 1's |
|
Puregon (Vial) 100 IU x 1's |
|
Puregon (Catridge) 150 IU/0.18 mL x 1's |
|
Puregon (Vial) 150 IU x 1's |
|
Puregon (Catridge) 300 IU/0.36 mL x 1's |
|
Puregon (Catridge) 600 IU/0.72 mL x 1's |
|
Puregon (Catridge) 900 IU/1.08 mL x 1's |
|
|
|
Manufacturer: |
Schering-Plough |
|
Distributor: |
Zuellig
|
|
|
|
